Royalty Pharma: The Failure It Had Already Insured, and the Raise Nobody Expected
A $150 million Lp(a) write-down, a third guidance hike in three quarters, a 20% tape, and a keyword list that quietly emptied of amyloid
RPRX · Earnings Call · 2026-11-04
Royalty Pharma: The Failure It Had Already Insured, and the Raise Nobody Expected
The wound that was stitched before it opened
On the surface, the third quarter was the same machine humming: Portfolio Receipts of $890 million, up 9%; Royalty Receipts up 9% in the quarter and 12% year-to-date; and a third consecutive raise to full-year guidance, now $3.50–3.55 billion of Portfolio Receipts and roughly 10–11% growth in recurring royalties versus the 7–10% previously guided. Pablo Legorreta opened with the line he has used all year, this time with an extra notch of emphasis: “we delivered 9% growth in Portfolio Receipts, our top line, and also in Royalty Receipts, which are our recurring cash flows” — Pablo Legorreta, Chief Executive Officer · 2026-11-04.
The quarter's actual news, though, was a failure. Novartis' pelacarsen missed its Phase III cardiovascular outcomes trial — the asset at the heart of the Lp(a) class Royalty Pharma had championed for six straight quarters. The company booked a $150 million non-cash impairment. That should have been the story.
It wasn't, because of the structure. Royalty Pharma bought into pelacarsen through a $500 million agreement with Ionis wrapped around stable, predictable Spinraza royalties. If pelacarsen worked, upside. If not, the Spinraza stream reverts to Ionis only after Royalty Pharma collects $550 million.
We also structured the pelacarsen investment in a protective way where we will still make our money back plus a small return.
The operative phrase there is the 1.1x return — genuinely new vocabulary in this company's earnings language this quarter.
The contrast with the prior calls is what makes it readable. In February, Marshall Urist was still telling analysts “we are still eagerly awaiting the results from Novartis this year” — Marshall Urist, Executive · 2026-02-11. In November 2025, when Amgen flagged a slower-than-expected event rate on olpasiran, he had insisted “it doesn't change our view of the probability of success” — Marshall Urist, Executive, likely Head of Business Development or similar · 2025-11-05. Conviction, then. Capital preservation, now — and a promise that the second Lp(a) readout, Amgen's HORIZON trial, lands at AHA "this weekend," where Urist says the company will parse baseline Lp(a) and LDL and look for any sign pelacarsen itself played a role.
Guidance, and a tape that has already voted
The equity has decided the quarter was good. Royalty Pharma shares are up 20.5% over the last 90 days, a clean up-17-week line with no meaningful drawdown inside the window. That move reads against what preceded it: the full tape shows three consecutive down legs (-11%, -27%, -10%) before a +159% advance. This is a recovery, not a breakout.
The multiple has moved with it. Price to revenue sat at 12.7x at the last reported quarter, up roughly 40% year-on-year and within about 12% of its all-time peak. Not expensive for a business posting a 92.2% free-cash-flow margin, but it does raise the bar. With effective net cash of -$8.5 billion and a 2030 target of $4.7 billion in top line, the company now has to deliver rather than promise. Interest coverage of 1.4x on the last reported quarter is the quiet counterweight to all that financial flexibility talk.
A new word at the top of the list
The most revealing shift in this quarter's keyword set is what climbed to number one: private company. Historically, Royalty Pharma has narrated itself as the buyer of royalties created by public biotechs and big pharma. Asked whether private-company deals could become a bigger slice, Legorreta was emphatic that the model is open-ended and carries no restriction on dealing with private or public counterparties — pointing to Servier, Voranigo and Ferring as proof it already happens, and noting that for private companies capital access is harder, which is precisely where a low-cost balance sheet earns its keep. For a franchise built on being the deepest-pocketed buyer of drug economics, declaring the aperture open-ended in private markets is a strategic tell: the next leg of deal flow may come from sellers who cannot reach public capital at all.
The other engine is R&D co funding, which has been building for several quarters and is now framed as a distinct growth leg. Chris Hite put a number on it: “we announced $1 billion of R&D co-funding deals, $500 million with J&J and $500 million with Teva” — Christopher Hite, Head of R&D Co-funding or similar senior R&D role · 2026-11-04, adding that the accounting treatment — contra-R&D under US GAAP — is what unlocks the market. That precedent, not the cash, is the moat; a competitor with identical capital cannot bid for the same dollars without it. The addressable pool is framed against R&D budgets expected to exceed $1 trillion over five years.
Two brand-new product keywords fill out the quarter: Polycythemia vera, attached to the $100 million Takeda/Zealand Mimrylo royalty, and Zoryve, the 3% Arcutis/AstraZeneca topical royalty. Both were described with the same phrase — an unlevered IRR in the low double digits — the discipline line the company reaches for when the market is watching for overpayment. Even the ESG item is new: a AAA ESG rating by MSCI, the kind of token a management team highlights when it wants to read as a mainstream, index-friendly compounder rather than a specialist financial buyer.
Confluence — and the slide that emptied
The strongest external corroboration came from another reporter. Amgen's DeLLphi 305 — the tarlatamab/Imdelltra first-line small cell lung cancer maintenance data — is a top-25 market-wide keyword this quarter, ringing the same bell Royalty Pharma has been sounding. Urist was candid about what it means: “the data was ahead of our expectations” — Marshall Urist, Chief Investment Officer · 2026-11-04. The stream was bought from BeOne for roughly $900 million and is shared with BeOne above $1.5 billion in sales — a tier Coyne was pressed on repeatedly and answered only in shape, not numbers.
What fell off the list is just as telling. Last quarter's top keywords — TTR amyloidosis, ATTR CM, cliramitug, Myqorzo — are absent from this quarter's top-30 entirely. The development stage investing narrative has rotated from cardiovascular and amyloid toward oncology and rare blood. China, a headline theme for three straight calls under China strategy, has demoted itself to a Q&A answer: Ken Sun is on the ground, the tracking funnel exists, no deal to show. Meanwhile Revolution Medicines declined its third funding tranche, and Coyne's response was a shrug: “On Rasonque, no impact on 2030.” — Terrance Coyne, Chief Financial Officer · 2026-11-04
The bottom line
Royalty Pharma just demonstrated that its underwriting works at the worst possible moment — an Lp(a) blow-up that cost book value but not the thesis — and raised guidance anyway. The market rewarded it with a 20% quarter and a multiple back near its historical ceiling. But leverage is real, coverage has thinned, and the next genuine swing factor is Amgen's HORIZON data this weekend. If olpasiran also fails, the protective-wrapper argument gets tested twice in consecutive quarters, and the re-rating will have front-run the answer.